¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Transient Receptor Potential Channels"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • potential difference
    ÀüÀ§Â÷
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • potential energy
    ÀüÀ§¿¡³ÊÁö, À§Ä¡¿¡³ÊÁö
  • potential gradient
    ÀüÀ§±â¿ï±â, ÀüÀ§Â÷
  • potential surface
    ÀüÀ§¸é
  • potential trauma
    ÀáÀç¿Ü»ó
  • pathogenic potential
    ¹ßº´´É
  • phase boundary potential
    »ó°èÀüÀ§
  • redox potential
    »êȭȯ¿øÀüÀ§
  • reduction potential
    ȯ¿øÀüÀ§
  • resonance potential
    °ø¸íÀüÀ§
  • resting membrane potential
    ¾ÈÁ¤¸·ÀüÀ§
  • reversal potential
    ¿ªÀüÀüÀ§
  • rheobasic potential
    ±âÀüÀ§
  • somatosensory evoked potential
    ¸ö°¨°¢À¯¹ßÀüÀ§°Ë»ç, ü¼º°¨°¢À¯¹ßÀüÀ§°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • negative potential
    À½ÀüÀ§
  • nerve action potential
    ½Å°æÈ°µ¿Àü¾Ð
  • oscillatory potential
    Áøµ¿¼ÒÆÄÀüÀ§
  • oxidation-reduction potential
    »êȭȯ¿øÀüÀ§
  • potential
    ÀüÀ§, °¡´É¼º, ÀáÀç·Â
  • pacemaker potential
    ½É¹ÚÁ¶À²±âÀü¾Ð, ÇâµµÀâÀÌÀüÀ§, ÆäÀ̽º¸ÞÀÌÄ¿ÀüÀ§
  • pathogenic potential
    ¹ßº´´É
  • phase boundary potential
    »ó°èÀüÀ§
  • plate potential
    ÆÇÀüÀ§
  • plateau potential
    °í¿øÀüÀ§, °í¿øÀü¾Ð
  • polarizing potential
    ºÐ±ØÀüÀ§, ºÐ±ØÀü¾Ð
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • potential surface
    ÀüÀ§¸é
  • potential trauma
    ÀáÀç¿Ü»ó
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • receptor organ
    ¼ö¿ë±â°ü(áôé»Ðïί).
  • receptor sensitivity
    ¼ö¿ëü °¨¼ö¼º
  • receptor site
    ¼ö¿ëüºÎÀ§.
  • receptor stimulants
    ¼ö¿ëüÀÚ±ØÁ¦.
  • receptor supersensitivity
    ¼ö¿ëü Ãʰ¨¼ö¼º(áôéÄô÷ õ±Êïáôàõ)
  • receptor, T cell
    T¼¼Æ÷(Ç׿ø)¼ö¿ëü
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • retinoic acid receptor
    ·¹Æ¼³ëÀλê¼ö¿ëü
  • retinoid acid receptor alpha=RARA
    ¾ËÆÄ·¹Æ¼³ëÀÍ»ê¼ö¿ëü
  • secondary receptor
    ÀÌÂ÷¼º ¼ö¿ë±â(¡­áôé»Ðï).
  • sensory receptor
    °¨°¢¼ö¿ëü.
  • sigma receptor
    ½Ã±×¸¶¼ö¿ëü
  • silent receptor
    ¹«¹ÝÀÀ¼ö¿ëü.
  • soluble interleukin-2 receptor
    °¡¿ë¼º ÀÎÅÍ·çŲ-2 ¼ö¿ëü
  • spare receptor
    ¿©ºÐ¼ö¿ëü.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
TIA transient ischemic attack; tumor-induced angiogenesis; turbidimetric immunoassay
TIE transient ischemic episode
TMB transient monocular blindness
TNH teaching nursing home; transient neonatal hyperammonemia
TOH transient osteoporosis of hip
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
APD(50) Action potential duration
APD90 Action potential duration
APD(50) Action potential duration at 50
APD(90) Action potential duration at 50% and 90
APD90 action potential durations at 90% repolarization
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
hormone receptor assay A diagnostic test to determine whether a breast cancer's growth is influenced by hormones or if it can be treated with hormones.
(09 Oct 1997)
purinergic receptor <biochemistry> Receptors that use purine nucleotides (e.g. ATP) as ligands.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
S-receptor kinase <enzyme> Srk - s-receptor kinase; from brassica oleracea; amino acid sequence has been determined
Registry number: EC 2.7.1.-
Synonym: srk gene product
(26 Jun 1999)
steroid receptor Family of nuclear transcription factors, most of which are receptors for hormones of the steroid family, for example androgen, oestrogen, glucocorticoid, mineralocorticoid, progesterone, retinoic acid, ecdysone, thyroid hormone and the Drosophila transcription factors knirps, ultraspiracle and seven up. This family contains a conserved domain (the steroid finger motif) containing two C4 type zinc fingers.
(18 Nov 1997)
nicotinic acetylcholine receptor Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range).
(18 Nov 1997)
nicotinic cholinergic receptor A class of receptors responsive to acetylcholine that also are activated by nicotine; ganglionic (including the adrenal medulla) and neuromuscular receptors. Two classes exist: nicotinic-neuronal and nicotinic-muscular.
(05 Mar 2000)
NMDA receptor A type of glutamate receptor that participates in excitatory neurotransmission and also binds N-methyl-d-aspartate; may be particularly involved in the cell damage observed in individuals with Huntington's disease.
(05 Mar 2000)
N methyl D aspartate receptor <physiology> Glutamate receptor sub type (see excitatory amino acids). N methyl D aspartate receptor channels seem to be potentiated by intracellular arachidonic acid.
Acronym: NMDA
(26 Mar 1998)
quisqualate receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
insulin receptor Areas on the outer part of a cell that allow the cell to join or bind with insulin that is in the blood. When the cell and insulin bind together, the cell can take glucose (sugar) from the blood and use it for energy.
(09 Oct 1997)
insulin receptor protein-tyrosine kinase <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of the insulin receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
insulin receptor substrate-1 protein <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous
Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1
(05 Dec 1998)
oestrogen receptor <cell biology> Cytoplasmic proteins that bind oestrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of oestrogen receptors in breast cancer patients has become clinically important and determines the likelihood of response to anti-oestrogen therapy with tamoxifen.
(17 Jul 2002)
olfactory receptor cells Very slender nerve cell's, with large nuclei and surmounted by six to eight long, sensitive cilia in the olfactory epithelium at the roof of the nose; they are the receptors for smell.
Synonym: olfactory cells, Schultze's cells.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á